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BACKGROUND: There is a large body of literature which assessed the incidence and risk factors of 
eclampsia, but little was done in assessing the association of clinical features and biological markers with 
prepartum and postpartum eclampsia.      
METHODS: A total of 361 eclamptic women admitted to three teaching hospitals between 2008 and 2013 
were included in this analysis. A comparative analysis was done for several clinical and biological 
variables to assess their association with prepartum and postpartum eclampsia.  
RESULTS: The overall incidence of eclampsia was 1.2% (prepartum 71% and postpartum 29%). The 
majority of women with prepartum eclampsia were young, primigravida, more hypertensive, symptomatic 
and proteinuric. Conversely, the majoritys of the women with post-partum eclampsia were adult, 
multiparous, carrying pregnancy to term, anemic, thrombocytopenic, and with hepatic dysfunction. The 
commonest severity symptom (headache) was less common in postpartum eclamptic women. 
CONCLUSION: The incidence of eclampsia was among the highest in the world. And, the analysis has 
shown that the clinical and biochemical spectrum of prepartum and postpartum eclampsia were 
apparently different. The majority of the women who developed postpartum eclampsia were multiparous 
and adult. Derangement of biomarkers was also more common in women with postpartum eclampsia.  
KEYWORDS: clinical features, comparative analysis, Ethiopia, incidence, organs dysfunction, 
prepartum, postpartum 
 




Eclampsia is one of the commonest causes of 
maternal and perinatal morbidity and mortality 
worldwide, the majority being in developing 
countries (1,2). It may complicate 2% to 3% of 
severely preeclamptic women not given 
anticonvulsant prophylaxis, and about 0.6% of 
those women receiving the anticonvulsant 
prophylaxis (3,4). The overall incidence of 
eclampsia in developed and developing countries 
is estimated to be 1.6 to 10 and 6 to 157 per 
10,000 deliveries, respectively (3,5,6).    
         Eclampsia is characterized by the occurrence 
of generalized tonic-clonic seizure and/or coma in 
pregnant or postpartum women with preeclampsia, 
and is not caused by epilepsy or other convulsive 
disorders (7-9). It is well known that eclampsia 
can occur during pregnancy (antepartum), during 
labor and delivery (intrapartum), and after 
delivery (postpartum) (10,11). 
        To date, however, there are no reliable 
biological tests to predict which pregnant or 
postpartum women will have 
preeclampsia/eclampsia (12). Clinical features and 
laboratory findings are also nonspecific but 
commonly used as a surrogate marker for the 
effect of the disease on organs/systems and as a 
warning sign for eclampsia (13). The challenge is 
that eclampsia can occur without clinical or 
biological evidences of preeclampsia (14-16).  
There is a large body of literature on 
eclampsia, which described its incidence before, 
during and after delivery, factors associated with 
its occurrence and the risks of maternal and 
perinatal mortality taking the overall eclampsia as 
a denominator (7,17-21). However, there is a
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paucity of data that assessed the risk factors and 
its complications disaggregated by onset of 
eclampsia.  
One study investigated maternal and obstetric 
factors associated with delayed and early 
postpartum eclampsia (22). Only delayed 
eclampsia cases were also compared with 
preeclamptic mothers with no eclampsia in the 
postpartum period (23). Other studies assessed 
only the magnitude of fetal and/or maternal 
mortality by type of eclampsia (24,25). In another 
study, some clinical features and proteinuria were 
compared in 46 antepartum and postpartum 
eclamptic women (26). Recurrence of convulsion 
in different types of anticonvulsant was assessed 
by different types of eclampsia (27). Antepartum 
and intrapartum eclampsia were also assessed for 
mode of delivery (28). Relatively, better 
characterization of eclampsia by type was done in 
a Scandinavian study (29).  
To our knowledge, this is the first study that 
investigated several variables in relation to 
prepartum and postpartum eclampsia. Thus, the 
objective of the study was to assess the association 
of selected clinical features and biological markers 




Study design, setting and participants: The 
current analysis was performed from a six year 
retrospective cohort study database, which was 
collected from three university teaching hospitals 
(Hawassa, Hosanna and Yirgalem) in the South 
regional state of Ethiopia. A comparative analysis 
(prepartum vs postpartum eclampsia) was done for 
several clinical and biological variables. All 
eligible women with eclampsia admitted to the 
study hospitals during the study period (2008 to 
2013) were included. The exclusion criterion was 
lost or incomplete data.  
The study hospitals were functioning as 
referral centers for the region and teaching center 
for public universities and private health colleges. 
In these hospitals, eclampsia was diagnosed with 
the onset of generalized tonic-clonic seizure 
and/or coma in pregnant or postpartum women 
commonly with clinical and/or laboratory features 
of preeclampsia. The most senior person’s 
(gynecologist, resident or general practitioner) 
clinical assessments and decisions were taken as a 
final source of data for this analysis. 
The commonly assessed clinical features for 
women with eclampsia were hypertension, 
headache, blurring of vision, epigastric pain, 
vomiting, urine output, bleeding tendency and 
generalized body swelling. Among others, dipstick 
and microscopic examination of urine, liver and 
renal function tests, and complete blood count 
were routinely performed in all study hospitals. 
Variables and data collection: Some of the 
variables assessed in association with the onset of 
eclampsia were: maternal age, parity, gestational 
age, prenatal care, number of fetuses, severity 
symptoms of HDP, degree of hypertension, 
episodes of convulsion, urine output, proteinuria, 
hemoglobin level, platelet count, creatinine level, 
serum oxaloacetic transaminase (SGOT) level, 
type of anticonvulsant or antihypertensive given, 
mode of delivery, fetal birth weight, perinatal and 
maternal outcome.   
The detail data were retrieved from patients’ 
charts. Each patient’s chart was accessed after 
identifying the eclampsia cases by their card 
number in the delivery log book. A structured data 
collecting format was prepared and used to 
abstract relevant data from the included patients’ 
charts. The data were abstracted by nine trained 
nurse data collectors (three for each hospital).  
Data analysis: Data were entered into a computer 
data analysis software program (Epi Info 7) to 
perform a comparative analysis. We used 
frequencies and proportions to describe the 
characteristics of the included variables with 
stratification by total eclampsia, prepartum and 
postpartum onset of eclampsia. A statistically 
significant association was considered when the p-
value was < 0.05. A flow diagram was used to 
select the study participants and a bar graph was 
constructed to show the proportion of eclampsia 
stratified by onset.  
Operational definitions: Onset of eclampsia was 
classified based on occurrence of first convulsion 
as antepartum (before onset of labor), intrapartum 
(during labor and delivery), and postpartum (after 
delivery and before end of purperium). It was also 
reclassified as early onset (<34 weeks of 
gestation) and late onset (>=34 weeks of 
gestation). The postpartum eclampsia cases were 
also reclassified as early postpartum (<48 hours 
after delivery) and late postpartum (>=48 hours 
and <6 weeks after delivery).  
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For the purpose of this analysis, however, the 
antepartum and intrapartum onset of eclampsia 
were merged to prepartum eclampsia. This was 
done taking into account that the baby and 
placenta were still in utero in both antepartum and 
intrapartum onset of eclampsia. One of the 
etiologies incriminated for occurrence of 
preeclampsia/eclampsia is placental pathology (8).  
As a result, this study defines prepartum eclampsia 
in women who developed generalized tonic-clonic 
seizure before the delivery and after 28 weeks of 
gestation. Women included as postpartum 
eclampsia were those who developed generalized 
tonic-clonic seizure after the delivery of at least a 
28 week gestational age fetus and before 6 weeks 
of the postpartum period.   
Eclamptic women’s systolic and diastolic 
blood pressures (BP) after admission were 
grouped as <160 and >=160 mmHg, and <110 and 
>=110 mmHg, respectively. The laboratory results 
were also dichotomized in order to determine their 
association with prepartum and postpartum 
eclampsia. Significant proteinuria defined that the 
qualitative test revealed +2 and above or +1 if the 
specific gravity was <1.020. Serum glutamic-
oxaloacetic transaminase (SGOT) level raised by 
>=2-fold from the baseline and creatinine level 
>=1 mg/dl were considered as significantly raised. 
Platelet count <100,000/mm3 and hemoglobin 
level <12+gm/dl were taken as severe 
thrombocytopenia and anemia, respectively. 
Women with an age range of 15-24 years and 
25-49 years were categorized as youth and adult, 
respectively (30). Youth and young women, 
primigravida and nulliparous were used 
interchangeably. The term prepartum and pre-
delivery, postpartum and post-delivery were also 
used interchangeably.      
Ethical consideration: Hawassa University 
College of Medicine and health sciences, 
institutional review board (IRB) gave us the 
ethical clearance to conduct and publish this 
research. Since the study was retrospective by 
design, written consent from patients was not 
required. Patient records were anonymized and de-
identified by excluding identifiers from data 
collection format prior to analysis. Furthermore, 
anonymity was secured by analyzing and 




During the study period, there were 30,750 
deliveries in all study hospitals (Figure 1). Of 
which, 1098(3.6%) women were diagnosed to 
have hypertensive disorders of pregnancy (HDP). 
Out of the total HDP cases, 373 were registered as 
eclampsia. Twelve cases of eclampsia were 
excluded from analysis due to incomplete or lost 
data. Finally, 361 women with eclampsia were 
included for this analysis (1.2% of the total 
deliveries and 33% of the total HDP). These 
women were again regrouped as prepartum and 




















Figure 1: Flow diagram showing the study population selection 
 
Figure 2 shows the summary of the included 
eclamptic women as categorized by occurrence of 
first convulsion in relation to the gestational age 
and delivery. Out of 361 eclamptic women, the 
proportion of antepartum, intrapartum and 
postpartum eclampsia was 47%, 24% and 29%, 
respectively. In terms of gestational age, the early 
(<34 weeks) and late (>=34 weeks) onset 
eclampsia cases were 18% and 82%, respectively. 
Specific to postpartum eclampsia, early (<48 
hours after birth) and late/atypical (>=48 hours 
after birth) onset accounted for 79% and 21%, 
respectively. The range of late onset eclampsia 
was 60 hours to 10 days from the time of delivery; 
five patients developed eclampsia on the 10
th
 
postpartum day.  In 97% of the total eclamptics, 
the convulsion occurred at home or on the way to 
the study hospitals. 
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Figure 2: The distribution of eclampsia by timing of onset in relation to gestational age and delivery, 2008-
2013. 
 
Note. Onset of eclampsia was difined based on occurrence of first convulsion as: 
1) Antepartum (during pregnancy), intrapartum (during labor and delivery) and postpartum 
(after deivery) 
2) Early (< 34 weeks of gestation) and late (> = 34 weeks of gestation) 
3) Early postpartum (< 48 hours after delivery) and late postpartum (>= 48 hours after delivery) 
 
Table 1 shows the proportion of prepartum and 
postpartum eclampsia in relation to maternal age, 
selected clinical features and biomarkers. The 
ratio of eclampsia in youth and adults was almost 
1:1. However, the proportion of postpartum 
eclampsia was significantly higher in adults than 
in youths (63.8% vs 36.2%; P = 0.001). In terms 
of gestational age, more than two-thirds of the 
women with postpartum eclampsia (69.7%) 
experienced it at term. In other words, preterm 
eclampsia was significantly higher in prepartum 
than in postpartum eclampsia (P<0.0001).  
          The overall incidence of eclampsia was a 
little bit higher in multigravida than in 
primigravida women (53.2% vs 46.8%). Of 
interest, this analysis has strongly demonstrated 
that prepartum and postpartum eclampsia were 
mainly the diseases of primigravida and 
multigravida, respectively (P<0.0001). Out of the 
total primigravida eclamptic women, 96.4% 
(163/169) developed it during the prepartum 
period. Similarly, out of the total postpartum 
eclampsia cases, 94.3% occurred in multigravida 
women.  
         Among selected clinical features, severe 
systolic hypertensions (>=160 mmHg) were 
characteristics of prepartum eclampsia (60.2%). In 
other words, the majority of postpartum eclamptic 
women were having mild to moderate systolic 
hypertension (53.3%; P<0.05). However, the 
difference in diastolic hypertension in the two 
groups was not statistically significant. In the 
majority of both the prepartum and postpartum 
eclamptic women, the commonest severity 
symptom was headache (80.5% and 66.7%, 
respectively), with statistically significant 
difference between the two groups (P = 0.004). 
Epigastric pain was an uncommon symptom 
among postpartum eclamptic women (P<0.0001). 
There were no statistically significant differences 
between the two groups in relation to other clinical 
features like urine output and episodes of 
convulsion before and after initiation of 
anticonvulsants.  
        In the majority of selected biomarkers, this 
analysis has demonstrated statistically significant 
difference between women with prepartum and 
postpartum eclampsia. Significant proteinuria 
(P<0.001) and severe thrombocytopenia (P = 
0.009) were more common in women with 
prepartum than postpartum eclampsia. On the 
other hand, a high proportion of anemia (P<0.001) 
and >=2-fold raised in SGOT level was observed 
among women with postpartum eclampsia (P = 
0.005). The >=1mg raised in creatinine level in 
both prepartum and postpartum eclampsia was 
proportional, and occurred in nearly three-fifths of 
the total eclamptic women (59.6%).   
         In terms of place of delivery, the proportion 
in one group was the mirror image of the other: 
82% of prepartum eclamptic women gave birth in 
a health facility; 81.6% of postpartum eclamptic 





women gave birth at home without the assistance 
of skilled persons (P<0.0001). Almost all women 
with postpartum eclampsia and nearly three-
fourths of women with prepartum eclampsia 
delivered vaginally (P<0.0001).    
         The fetal birth weights in prepartum and 
postpartum eclamptic group were also 
significantly different: 75% of newborns of 
prepartum eclamptic women were having low 
birth weight; whereas, 87.6% of postpartum 
eclamptic women gave birth to newborns with 
normal birth weight (P<0.0001). As one of the 
outcome indicators, the proportion of perinatal 
death in women with prepartum eclampsia was 
significantly higher than the postpartum eclampsia 
(P<0.0001). With regard to the mothers, there was 
no statistically significant difference in maternal 
death and maternal hospital stay in the two groups.   
 





N = 361 
Prepartum 
(%) 
 N = 256 
Postpartum 
(%) 
 N = 105 
 
P-value 
Age in years:       15 – 24 










     Preterm (< 37 weeks) 














     Primigravida 












Prenatal care:      Yes 










     Singleton 












Systolic hypertension (ever):     
     < 160 mmHg 












Diastolic hypertension (ever): 
    < 110 mmHg 












Headache:      Yes 








Visual disturbance:      Yes 






  65(61.9) 
0.1 
Epigastric pain:     Yes 








Total episodes of convulsion before arrival:     < 10 












Any convulsion after initiation of anticonvulsant:    
Yes 













                                   Yes 












Urine output:  
      Normal 













        Insignificant 
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N = 361 
Prepartum (%) 
 N = 256 
Postpartum (%) 
 N = 105 
 
P-value 
Anemia (Hgb < 12 gm/dl): 
        Yes 













 (< 100, 000/mm3):      Yes   












Raised creatinine  
(>= 1gm/dl):          Yes 












Highest SGOT level: 
               < 2-fold raised 












Required antihypertensive:  
      Yes 













      MgSo4 












Place of delivery: 
       Health facility 












Mode of delivery: 
       Vaginal 













              Male  












Newborn birth weight (kg):  
           < 2.5  













    Discharged alive 













    Discharged alive 















The incidence of eclampsia in this study was more 
than four-fold higher than a global estimate (1.2% 
vs 0.28%) (7). Yet, our report was nearly in line 
with other reports from Nepal and Tanzania 
(31,32), and more than 3-fold lower than the 
reports from some centers in Nigeria and Pakistan 
(24,33,34). Specifically, the incidence of 
postpartum eclampsia (more than a quarter of the 
total) is consistent with several reports from both 
high and low income countries (26,29,35,36). The 
proportion of late postpartum eclampsia (21%) 
was also in between some previous reports, 14% 
and 15% (22,37) and 28% and 56% (36,38).  
Of interest, this analysis has shown that the 
clinical and biochemical spectrum of prepartum 
and postpartum eclampsia were different. Our 
main findings were that women with prepartum 
eclampsia were relatively young age, and the 
majority were primigravida, more hypertensive, 
symptomatic and proteinuric. Conversely, the 
majority of women who were at increased risk for 
post-partum eclampsia were adult, multiparous, 
having term pregnancy, anemic, 
thrombocytopenic, and with hepatic dysfunction.  
        The association of prepartum eclampsia with 
young age and primigravida is consistent with one 
previous report that assessed only antepartum and 
intrapartum eclampsia (39). Several other studies 
also showed the increased risk of eclampsia 
among primigravid and young women. However, 
none of these studies compared the predictor 





variables by stratifying the type of eclampsia as 
pre- and post-delivery; they reported that 
eclampsia is common in primigravida, age <25 
years by including either all types of eclampsia or 
only postpartum eclampsia as a denominator 
(5,21,27,37,38,40).  
       The increased risk of prepartum eclampsia 
among young and nulliparous women may not be 
as such controversial. As this study showed, 
however, the postpartum eclampsia was strongly 
associated with women who were multiparous and 
aged 25 years and above. Nevertheless, this 
finding is not in line with two previous studies, 
which assessed only postpartum eclampsia and 
reported the increased risk to primigravida and 
young age (37,38). As a result, we recommend 
further study to verify the age and parity spectrum 
in prepartum and postpartum eclampsia. 
        The significant association of prepartum and 
postpartum eclampsia with preterm and term 
pregnancies, respectively, was expected. This is 
because the majority of prepartum eclampsia cases 
(47%) were antepartum by onset; and antepartum 
eclampsias in turn were reported as being strongly 
associated with preterm pregnancies (Douglas and 
Redman, 1994) (40). This study also showed that 
about 38% of prepartum eclampsia occurred in 
preterm pregnancies while the proportion of 
preterm postpartum eclampsia was nearly three-
fold lower (13%). As a complimentary evidence, 
three-fourths of babies born to prepartum 
eclampsia were having low birth weight while the 
reverse was true for postpartum eclampsia.   
          Similarly, the significantly increased 
anemia, thrombocytopenia and evidence of hepatic 
dysfunction in women with postpartum eclampsia 
could be explained in two ways. Since the 
majority of women with postpartum eclampsia 
gave birth at home with no skilled person 
attendant, the possibility of more blood loss during 
delivery was probably unavoidable. Secondly, the 
relatively low proportion of headache and the 
lowest proportion of epigastric pain and blurring 
of vision among postpartum eclamptic women 
might have increased the chance for the disease to 
buy more time which might have resulted in more 
organs damage.       
           In this study, headache was the commonest 
prodromal symptom in both prepartum and 
postpartum eclampsia, which is consistent with 
several other studies (21,26,40). The relatively 
low proportion of epigastric pain and visual 
disturbance in women with postpartum eclampsia 
was also reported in Onuh et al study (40). The 
low proportion of severity symptoms in women 
with postpartum eclampsia might have contributed 
to failure of preventive actions prior to its 
occurrence.  
       Lastly, the significantly increased risk of 
perinatal mortality in women with prepartum 
eclampsia may not only be associated with the 
hypertensive disease itself. Since the majority of 
babies in preeclamptic women were born preterm 
and with low birth weight, the chance of survival 
in the early neonatal period might be low, which 
was also observed in other studies (7,31,40). 
         This study is not without limitation. Since 
our study is based on referral hospitals data, where 
the majority of eclamptic women were likely to 
come, the reported incidence may not represent 
the actual incidence of eclampsia in the general 
population. The denominator in the community is 
expected to be high due to the large number of 
deliveries at home and in the referring health 
facilities. Furthermore, since the majority of the 
included women were admitted to the study 
hospitals after the onset of convulsion, we were 
unable to assess their pre-convulsion status. 
Because of the delay in reporting, patients or 
relatives might not recall the exact time of onset of 
convulsion. As a result, some of the early onset 
postpartum eclampsia might be grouped as late 
onset. The documented histories, physical 
examinations and laboratory findings may not be 
always accurate.  
         In conclusion, the incidence of eclampsia in 
this study was high, but not as high as some other 
reports. More than a quarter of the total were 
postpartum eclampsia. This analysis demonstrated 
that prepartum eclampsia was mainly the disease 
of nulliparous and young women. On the other 
hand, the majority of women who developed 
postpartum eclampsia were multiparous and adult. 
The commonest severity symptom was headache, 
but was less common in postpartum than 
prepartum eclamptic women. Derangement of 
biomarkers was more common in postpartum 
eclampsia. Since this is probably the first study 
that assessed the association of several variables 
with prepartum and postpartum eclampsia, similar 
studies are highly recommended.    
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